BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7512271)

  • 1. Clinical evaluation of serum alpha-fetoprotein (AFP) and protein induced by vitamin K absence or antagonist-II (PIVKA-II) levels in patients with hepatocellular carcinoma following interventional radiology.
    Minakuchi K; Murata K; Kaminoh T; Takada K; Takashima S; Nakamura K; Onoyama Y
    Radiat Med; 1993; 11(6):231-6. PubMed ID: 7512271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathologic significance of protein induced vitamin K absence or antagonist II and alpha-fetoprotein in hepatocellular carcinoma.
    Nakagawa T; Seki T; Shiro T; Wakabayashi M; Imamura M; Itoh T; Tamai T; Nishimura A; Yamashiki N; Matsuzaki K; Sakaida N; Inoue K; Okamura A
    Int J Oncol; 1999 Feb; 14(2):281-6. PubMed ID: 9917503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: a meta-analysis.
    Caviglia GP; Ribaldone DG; Abate ML; Ciancio A; Pellicano R; Smedile A; Saracco GM
    Scand J Gastroenterol; 2018 Jun; 53(6):734-740. PubMed ID: 29667463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis.
    Kishi K; Sonomura T; Mitsuzane K; Nishida N; Kimura M; Satoh M; Yamada R; Kodama N; Kinoshita M; Tanaka H
    Radiat Med; 1992; 10(5):189-95. PubMed ID: 1279748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes.
    Kasahara A; Hayashi N; Fusamoto H; Kawada Y; Imai Y; Yamamoto H; Hayashi E; Ogihara T; Kamada T
    Dig Dis Sci; 1993 Dec; 38(12):2170-6. PubMed ID: 7505217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
    Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
    Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.
    Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH
    Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
    Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
    Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
    Feng H; Li B; Li Z; Wei Q; Ren L
    BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic value of serum alpha-fetoprotein, alpha-fetoprotein variant and abnormal prothrombin in primary hepatocellular carcinoma].
    Hu RZ; Zhao SQ; Shen B; Guo GB
    Zhonghua Gan Zang Bing Za Zhi; 2019 Aug; 27(8):634-637. PubMed ID: 31594082
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.
    Seo SI; Kim HS; Kim WJ; Shin WG; Kim DJ; Kim KH; Jang MK; Lee JH; Kim JS; Kim HY; Kim DJ; Lee MS; Park CK
    World J Gastroenterol; 2015 Apr; 21(13):3928-35. PubMed ID: 25852278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
    Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prothrombin induced by vitamin K absence or antagonist-II (PIVKA-II) predicts complete responses of transarterial chemoembolization for hepatocellular carcinoma.
    Wang SY; Su TH; Chen BB; Liu CJ; Liu CH; Yang HC; Tseng TC; Chen PJ; Kao JH
    J Formos Med Assoc; 2022 Aug; 121(8):1579-1587. PubMed ID: 35078686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of PIVKA-II After Living-donor Liver Transplantation for Hepatocellular Carcinoma.
    Park MS; Lee KW; Kim H; Choi YR; Hong G; Yi NJ; Suh KS
    Transplant Proc; 2017 Jun; 49(5):1109-1113. PubMed ID: 28583537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
    Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
    Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.